Key result
High plasma FGF21 linked to ~3.7-fold higher all-cause mortality in metabolic syndrome.
Why the study?
Fibroblast growth factor 21 (FGF21) is elevated in metabolic syndrome (MetS), but its role in the pathogenesis of cardiovascular disease remains controversial, motivating an evaluation of the association between plasma FGF21 levels and long-term mortality in MetS patients.
Cohort (n=202)
Answers are grounded in this paper and cite their sources.
Reveals elevated plasma fibroblast growth factor 21 is independently linked to higher all-cause mortality in metabolic syndrome, highlighting its potential value as a long-term prognostic biomarker.
Background Metabolic syndrome (MetS), a cluster of interrelated cardiovascular risk factors, is associated with increased risk of cardiovascular and non-cardiovascular disease. Fibroblast growth factor 21 (FGF21) plays an important role in metabolic regulation and has been shown to be elevated in MetS. However, role of FGF21 in pathogenesis of cardiovascular disease is still controversial. Objective We aimed to identify the association between plasma FGF21 level and long-term mortality in MetS patients. Methods Patients with MetS were enrolled in this study during 2015–2017. Blood samples for FGF21 were collected after 12-hour fasting and plasma FGF21 levels were determined using a human FGF21 enzyme-linked immunosorbent assay (ELISA) at the first time of the enrollment. Clinical parameters, and all-cause mortality were recorded. Cox-proportional hazard regression was used for the analysis of association between plasma FGF21 level and all-cause mortality. Results A total of 202 Mets patients (male 44.6%) with mean age of 64.3±8.3 years and BMI of 27.3±5.4 kg/m2 were enrolled. After a median follow up of 80 months, 32 (15.8%) patients died. Multivariable Cox proportional hazard regression showed that FGF21 level was independently associated with all-cause mortality after adjustment for age, established cardiovascular disease, estimated glomerular filtration rate and left ventricular ejection fraction. Patients with FGF21 level above median (240 pg/ml) had higher risk of all-cause death compared to patients with FGF21 ≤240 pg/ml (hazard ratio [HR], 3.66; 95% confidence interval [CI], 1.24–10.82; p=0.019) (Figure 1). Conclusion FGF21 level is independently associated with long term mortality in metabolic syndrome. Funding Acknowledgement Type of funding sources: Public Institution(s). Main funding source(s): Thailand research fund
No takes yet. Share an insight, caveat, or question.
Phrommintikul et al. (2022) conducted a cohort in Metabolic syndrome (n=202). Plasma FGF21 level above median (>240 pg/ml) vs. Plasma FGF21 level ≤240 pg/ml was evaluated on All-cause mortality (HR 3.66, 95% CI 1.24-10.82, p=0.019). Plasma FGF21 >240 pg/ml was independently associated with higher all-cause mortality vs ≤240 pg/ml in metabolic syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: